Novartis Investigative Site

Toyota, Aichi-ken 471-8513

0 studies enrolling now · 3 studies all time

What they study most

Atherosclerotic Cardiovascular Disease, IgA Nephropathy, Primary IgA Nephropathy

Studies at this site

• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed